Vol 49 No 05

May 03, 2021

The test can help clinician determine whether a second procedure would be of benefit to a patient.

May 03, 2021

Physician involvement in responses to payer audits is crucial.

April 29, 2021

"Three decades into prostate-specific antigen screening–detected prostate cancer, the prognostic and therapeutic impacts of various types of pelvic lymph node dissection remain unclear," writes Badar M. Mian, MD.

April 22, 2021

Any aha! moments usually come before trial begins.

April 16, 2021

Review of nearly 5600 patients found a 5% pooled incidence of postoperative urosepsis.

April 15, 2021

A phase 3 trial has already been launched to build on these early results with the combination of the PARP inhibitor and androgen receptor inhibitor.

April 15, 2021

Odds of having UI were 56% higher in women with vs women without diabetes.

April 14, 2021

The PSMA-targeted radiopharmaceutical 177Lu-PSMA-617 is poised to become one of the first PSMA theranostics approved by the FDA.

April 14, 2021

Depression appears to be common in patients, retrospective data indicate.

April 13, 2021

The Optilume drug-coated balloon catheter system is used to treat patients with lower urinary tract symptoms related to benign prostatic hyperplasia.

April 07, 2021

Ninety-eight percent of the study population was female.

April 06, 2021

Using a blood or saliva sample, ProstateNow employs a 3-pronged approach for assessing risk.

March 22, 2021

Scott T. Tagawa, MD, explained the latest developments with the radiopharmaceutical radium-223 at the 2021 New York GU 14th Annual Interdisciplinary Prostate Cancer Congress®.